Clinical Framework for Motor Rehabilitation in Parkinsonism: Integrating Individualized and Syndrome-Specific Approaches

Abstract

This review presents a clinical framework for motor rehabilitation in patients with Parkinson’s disease and atypical parkinsonian syndromes. Its purpose is to provide practical, individualized rehabilitation strategies that consider both disease stage and the clinical characteristics of each syndrome. Motor symptoms such as bradykinesia, rigidity, postural instability, and gait disturbance are major contributors to disability and reduced independence in these populations. Although pharmacological treatment remains fundamental, rehabilitation is crucial for maintaining mobility and preventing falls. This review discusses stage-based approaches, including early education in self-management and compensatory movement strategies, as well as advanced interventions for patients with severe motor dysfunction. Syndrome-specific features are also addressed. For example, patients with progressive supranuclear palsy often exhibit early axial rigidity and postural extension, while those with multiple system atrophy may experience cerebellar ataxia or autonomic dysfunction. In corticobasal degeneration, motor planning deficits and sensory loss may resemble symptoms seen in cortical stroke. Additionally, the review emphasizes the importance of recognizing and managing dystonia, which can further impair motor function and safety. While the primary focus is on motor symptoms, the influence of non-motor features such as cognitive impairment and autonomic instability is also acknowledged in rehabilitation planning. Overall, this review aims to support clinical decision-making through a structured, patient-centered approach to motor rehabilitation in parkinsonism.

Highlights

• • Emphasizes motor rehabilitation for Parkinson’s disease and related syndromes.

• • Tailor strategies to distinct motor profiles in atypical parkinsonian syndromes.

• • Highlights the role of dystonia assessment and treatment in motor rehabilitation.

INTRODUCTION

Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide, first described in 1817 by James Parkinson [1,2]. Since its original characterization, extensive clinical observations and research have greatly expanded our understanding of its pathological mechanisms and clinical manifestations. The core pathophysiology of PD involves progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to dysfunction of the basal ganglia–cortical circuitry and resulting in impaired motor control. A pathological hallmark of PD is the presence of Lewy bodies—abnormal intracellular protein aggregates composed primarily of misfolded alpha-synuclein—which are thought to contribute to neuronal death and the emergence of the classic motor symptoms [1]. These include bradykinesia, muscular rigidity, resting tremor, and postural instability. In addition to motor symptoms, PD is frequently associated with non-motor features such as autonomic dysfunction, including orthostatic hypotension and urinary disturbances. Notably, gait disturbances may result from both motor and non-motor impairments, representing a major source of disability that profoundly affects functional independence and quality of life [3,4].

Atypical parkinsonian syndromes (APSs) refer to a group of neurodegenerative disorders that share parkinsonian motor features with PD but are pathologically and therapeutically distinct [5]. These include multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB) [6]. Each syndrome has its own distinct pathology. PSP and CBD are classified as tauopathies, characterized by abnormal intracellular accumulation of hyperphosphorylated tau protein. In contrast, MSA is an alpha-synucleinopathy, like PD, but the abnormal alpha-synuclein inclusions in MSA are primarily located in oligodendrocytes rather than neurons. DLB also shares Lewy bodies with PD but differs in that it is marked by earlier and more severe cognitive decline. These pathological differences contribute to variations in clinical presentation, timing and pattern of symptom onset, and differential responses to dopaminergic therapy [5,6]. Importantly, APSs frequently present with early and prominent non-motor symptoms such as cerebellar ataxia or severe autonomic failure, requiring tailored approaches to rehabilitation planning.

This review comprehensively examines the clinical considerations relevant to developing effective rehabilitation strategies for motor symptoms in individuals with PD and APSs. Given the heterogeneity of pathological mechanisms and symptom profiles, individualized rehabilitation approaches that reflect syndrome-specific features are essential for optimizing patient outcomes.

CLINICAL CHARACTERISTICS, DIAGNOSIS, AND SYMPTOMATOLOGY OF PD

PD is primarily diagnosed through clinical evaluation. The UK PD Society Brain Bank Criteria remains one of the most widely used diagnostic frameworks, identifying bradykinesia as an essential feature accompanied by at least one additional symptom such as rigidity, resting tremor, or postural instability [7]. However, these motor symptoms often become more apparent in the later stages, which complicates early diagnosis.

Characteristic gait abnormalities in PD include freezing of gait (FOG) and magnetic gait [4]. FOG is defined by a sudden inability to initiate or continue walking, especially in narrow spaces or during directional changes, markedly increasing fall risk. Magnetic gait is characterized by short, shuffling steps as though the feet were “glued” to the floor. Both manifestations reflect basal ganglia dysfunction and serve as important markers for assessing disease severity and planning rehabilitation strategies.

PD is associated not only with motor symptoms but also with a broad range of non-motor symptoms, including cognitive decline, mood disturbances, autonomic dysfunction, and sleep disorders [8]. Autonomic dysfunction, such as orthostatic hypotension and urinary disturbances, can independently impair balance and gait, contributing to falls and disability even in the absence of prominent motor decline. These non-motor features are essential to comprehensive patient evaluation and must be integrated into rehabilitation planning.

ASSESSMENT OF DISEASE SEVERITY AND GOAL SETTING IN PD REHABILITATION

Accurate assessment of disease severity is crucial for individualized rehabilitation. The Hoehn and Yahr (H&Y) staging system categorizes PD into five stages based on motor progression and functional impairment, ranging from unilateral involvement (stage 1) to complete immobility (stage 5) [9]. In addition, the Unified PD Rating Scale provides a multidimensional evaluation encompassing motor and non-motor symptoms, daily living activities, and treatment response.

The goals of rehabilitation in PD extend beyond symptom control. The primary aim is to preserve functional independence, delay disease progression, and improve quality of life. Rehabilitation strategies must therefore be adapted to the individual’s disease stage and functional status, incorporating interventions directed at motor improvement, balance maintenance, and non-motor symptom management (Table 1).

Table 1. Rehabilitation strategies according to disease severity in PD.

PD stage	Clinical characteristics	Rehabilitation goals	Recommended interventions
Early (H&Y 1–2)	Unilateral or mild bilateral symptoms, no postural instability	Promote physical activity, educate on medication timing, initiate self-management	Aerobic exercise, LSVT BIG, compensatory cueing strategies, education on “on-off” phenomenon
Mid (H&Y 2.5–3)	Postural instability, bilateral symptoms, increased risk of falls	Maintain mobility and balance, reduce fall risk, adapt home environment	Balance training, external cues, rhythmic auditory stimulation, dual-task training, home safety evaluation
Advanced (H&Y 4–5)	Severe disability, may be wheelchair-bound or bedridden	Preserve quality of life, manage complications, caregiver support	Assistive devices, passive range of motion, caregiver education, respiratory therapy, contracture prevention

PD, Parkinson’s disease; H&Y, Hoehn and Yahr; LSVT, Lee Silverman Voice Treatment.

REHABILITATION APPROACHES FOR MOTOR SYMPTOM MANAGEMENT IN PARKINSONISM: TIMING, PATIENT EDUCATION, AND SELF-DIRECTED STRATEGIES

Importance of early rehabilitation and medication education

Although rehabilitation provides substantial benefits in PD, particularly for patients in H&Y stages 2–3, pharmacological therapy remains the cornerstone of management [4,10,11]. Patient and caregiver education should emphasize that rehabilitation is a supportive intervention to maintain function, not a treatment to reverse disease progression. Education should also include guidance on the on-off phenomenon, where motor fluctuations occur due to changes in medication efficacy, encouraging patients to schedule physical activity during “on” periods [12].

Self-management and compensatory strategies

Early initiation of self-management exercise and compensatory strategies is essential [4,13]. Self-directed programs such as aerobic training, strength conditioning, Nordic walking, dance, tai chi, aquatic therapy, and exergaming have been shown to improve gait, balance, and quality of life [14,15]. These approaches align with the principles of large-amplitude functional task exercise, exemplified by interventions like LSVT® BIG, which emphasize movement amplitude and sensorimotor integration [16,17].

Compensatory strategies include external cues (visual, auditory, somatosensory) and internal cues (self-instruction, cognitive rehearsal), which bypass impaired basal ganglia circuits by engaging alternative motor pathways. Techniques such as rhythmic cueing, motor imagery, and training in novel walking patterns (e.g., side-stepping, exaggerated stepping) can be applied to enhance gait. In cases of severe motor impairment, adaptive methods such as cycling or scooter use may be necessary [18].

From restoration to adaptation: managing decline

As PD advances, impairments in muscle strength, flexibility, and coordination often become more pronounced. When well-structured rehabilitation fails to yield functional improvement, the focus should transition from restoration to adaptation. This involves maximizing residual function and modifying daily activities to maintain independence and quality of life.

REHABILITATION-BASED MANAGEMENT OF MOTOR SYMPTOMS IN APSs

APSs, including MSA, PSP, CBD, and DLB, present with parkinsonism but differ in their underlying pathology, clinical progression, and therapeutic response [19,20,21]. While some rehabilitation strategies overlap with those used in idiopathic PD, the syndrome-specific features of each disorder necessitate tailored approaches (Table 2).

Table 2. Clinical features and rehabilitation strategies in atypical parkinsonian syndromes.

Syndrome	Pathophysiology	Key clinical & diagnostic features	Rehabilitation considerations
MSA-P/MSA-C	α-synucleinopathy	MSA-P: Parkinsonism with early autonomic dysfunction (e.g., orthostatic hypotension); poor levodopa response. MSA-C: Cerebellar ataxia. Both subtypes have rapid progression and high fall risk.	Balance and coordination training, orthostatic management, adaptive aids
PSP	Tauopathy	Early postural instability, vertical gaze palsy, axial rigidity. Poor levodopa response. Early falls and rapid functional decline are typical.	Axial stretching, gaze compensation, specialized walkers, caregiver education
CBD	Tauopathy	Asymmetric rigidity, limb dystonia, apraxia, cortical sensory loss. Prognosis is poor with limited therapeutic response.	Stroke-like rehab principles, sensory re-education, motor planning support
DLB	α-synucleinopathy (with amyloid/tau overlap)	Cognitive fluctuation, early hallucinations, parkinsonism. Rehab potential limited by fluctuating attention.	Simplified and structured tasks, visual cueing, errorless learning, caregiver guidance

MSA-P, multiple system atrophy–parkinsonian type; MSA-C, multiple system atrophy–cerebellar type; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; DLB, dementia with Lewy bodies.

MSA

MSA is a progressive neurodegenerative disorder that manifests with either parkinsonian or cerebellar features, leading to its classification into two primary subtypes: the parkinsonian variant (MSA-P) and the cerebellar variant (MSA-C). Both subtypes share the same underlying pathology—glial cytoplasmic inclusions composed of alpha-synuclein—but differ significantly in their predominant clinical manifestations and therapeutic priorities [20].

MSA-P is characterized by motor symptoms resembling idiopathic PD, including bradykinesia and rigidity. However, patients with MSA-P typically show little or no response to dopaminergic medications. A defining feature of the disorder is early and severe autonomic dysfunction, presenting as orthostatic hypotension, urinary incontinence, and erectile dysfunction, all of which must be carefully evaluated in rehabilitation planning. Rehabilitation in MSA-P focuses on managing parkinsonian motor features while also implementing strategies to reduce fall risk and accommodate autonomic instability [21].

In contrast, MSA-C presents primarily with cerebellar signs such as truncal and limb ataxia, dysmetria, and impaired motor coordination. These symptoms severely compromise postural control and gait stability. Rehabilitation for MSA-C therefore requires a direct focus on cerebellar dysfunction, with proprioceptive and coordination training as core elements. Specific interventions such as Frenkel exercises and balance training with visual or auditory biofeedback have proven particularly beneficial for improving coordination and reducing falls. Adaptive mobility aids and targeted safety education must also be tailored to address the unique challenges associated with cerebellar ataxia [20].

Although MSA-P and MSA-C fall within the same disease spectrum, distinguishing between these subtypes is critical, as MSA-C requires more specialized interventions targeting cerebellar dysfunction and motor coordination deficits.

PSP

PSP is a primary tauopathy, pathologically defined by the accumulation of hyperphosphorylated tau protein in subcortical structures and clinically by the early onset of axial rigidity, vertical gaze palsy, and profound postural instability [20]. Patients with PSP frequently develop pronounced axial rigidity and extensor tone. Coupled with the inability to perform vertical eye movements, these deficits often lead to compensatory extension of the neck and trunk to optimize visual fields, paradoxically worsening posterior instability. In addition, the executive dysfunction commonly seen in PSP results in poor hazard awareness, impulsivity, and inattentive gait, significantly heightening the risk of sudden, unprotected backward falls. These multifactorial challenges demand proactive clinical vigilance and a coordinated multidisciplinary rehabilitation approach.

Rehabilitation in PSP must prioritize fall prevention and postural control. Axial flexibility training and stretching exercises aimed at reducing extensor hypertonicity are essential. Gaze compensation strategies, such as training patients to employ coordinated head and neck movements to adjust visual fields, can partially offset vertical gaze limitations. Early prescription of specialized assistive devices, including weighted U-step walkers, has been shown to improve stability and decrease the risk of backward falls [19].

Another important priority is comprehensive education for patients and caregivers regarding the unique fall risks associated with PSP. Caregivers should be trained in environmental modifications and safety strategies to minimize hazards during daily activities, particularly those involving changes in head or eye position.

Given the progressive course of PSP and the early onset of axial rigidity and dystonic postures, routine assessment of axial tone, posture, and functional mobility is essential. In cases of severe axial dystonia, pharmacologic therapy, botulinum toxin injections, or neuromuscular re-education techniques may be appropriate adjunctive interventions.

CBD

CBD is a rare and clinically heterogeneous neurodegenerative disorder, pathologically defined by asymmetric frontoparietal cortical atrophy and tau-positive neuronal inclusions. The asymmetry in cortical involvement produces a combination of unilateral rigidity, apraxia, cortical sensory loss, and higher-order cognitive and language dysfunctions. Unlike idiopathic PD, which primarily results from subcortical dopaminergic depletion, CBD is a cortical–basal ganglia disorder involving both cortical and extrapyramidal structures [20].

A key feature of CBD is the unilateral degeneration of the frontal and parietal cortices, leading to deficits reminiscent of hemispheric stroke. Depending on the lateralization of cortical atrophy, patients may demonstrate ideomotor or ideational apraxia, impaired limb-kinetic planning, visuospatial disorientation, non-dominant neglect, or aphasia. Cortical sensory loss further compounds motor dysfunction by limiting proprioceptive feedback necessary for movement control. Clinicians and rehabilitation specialists must recognize that although CBD is progressive and degenerative, rather than vascular and acute, its impairments may closely resemble post-stroke hemiparesis. Consequently, rehabilitation strategies for CBD should draw from established stroke rehabilitation practices, with modifications that reflect the progressive nature of the disease. Task-specific, functional motor training should be emphasized, incorporating repetition, motor imagery, and bilateral coordination tasks to compensate for apraxia and cortical motor planning deficits. For patients with marked proprioceptive and tactile sensory loss, structured sensory re-education programs may enhance somatosensory awareness [19].

Cognitive and language impairments also require targeted intervention, particularly when the dominant hemisphere is affected. Cognitive rehabilitation should include strategies to strengthen attention, executive function, and praxis. Compensatory measures, such as augmentative communication aids and simplified language frameworks, can further support daily communication and independence.

DLB

DLB is a neurodegenerative disorder situated at the intersection of PD and Alzheimer’s disease, both pathologically and clinically. It is characterized by the accumulation of alpha-synuclein-containing Lewy bodies in cortical and subcortical regions, along with variable contributions of beta-amyloid and tau pathology. Clinically, DLB presents with a triad of progressive cognitive decline, parkinsonism, and prominent neuropsychiatric features, including recurrent visual hallucinations and fluctuations in attention and alertness [20].

Although dementia is often the earliest and most prominent symptom of DLB, motor features resembling parkinsonism frequently emerge as the disease progresses. Rehabilitation planning must therefore account for both motor and cognitive impairments. While motor deficits may be addressed with strategies similar to those used in idiopathic PD, the rehabilitation potential in DLB is strongly influenced by the severity and variability of cognitive impairment.

A major challenge in DLB rehabilitation lies in the reduced cognitive capacity for sustained attention, goal-directed activity, and consistent engagement in tasks. Executive dysfunction, visuospatial impairment, and fluctuating attention may compromise the patient’s ability to follow instructions, retain therapeutic strategies, and perform complex or multi-step exercises. As a result, even well-structured rehabilitation programs may have limited efficacy if they are not adapted to the patient’s cognitive profile. To optimize outcomes, interventions should be individualized and simplified, emphasizing structured, repetitive, and highly familiar physical tasks that reduce cognitive demand. The use of external cueing, visual supports, and errorless learning principles can help compensate for executive and memory deficits. Environmental modifications, such as minimizing visual and auditory distractions, further support functional mobility and safety [20].

In addition to motor rehabilitation, concurrent cognitive stimulation therapy may provide complementary benefits, particularly in sustaining engagement and preserving residual cognitive function. A collaborative approach involving physical therapists, occupational therapists, and neuropsychologists is critical to balancing motor training with cognitive limitations. Caregiver education also plays a central role, ensuring reinforcement of motor training, consistent use of compensatory strategies, and the maintenance of a safe and structured environment.

DYSTONIA IN PD AND APSs

Dystonia is a prominent and often disabling motor symptom in patients with PD and APSs. It contributes substantially to functional impairment, primarily through its association with pain, restricted mobility, and postural abnormalities. In PD, dystonia can occur even in the early stages but typically becomes more complex as the disease advances, particularly in the context of long-term dopaminergic therapy, where it may coexist with or resemble other forms of dyskinesia. Painful muscle contractions and fixed postures may exacerbate gait difficulties and further reduce quality of life.

In APSs, dystonia presents with variable clinical patterns depending on the underlying pathology. In PSP, axial rigidity emerges early and is combined with postural imbalance and vertical gaze palsy [6]. This combination significantly contributes to backward falls and poses major therapeutic challenges. Rehabilitation strategies in PSP must therefore target axial dystonia directly, integrating flexibility training, compensatory visual cueing techniques, and specialized assistive devices to reduce fall risk. Pharmacologic therapies for PSP-related dystonia are often limited in efficacy, prompting consideration of adjunctive interventions such as botulinum toxin injections for cervical or other axial muscle dystonia.

In MSA, dystonia frequently involves proximal or limb muscles. Patients with MSA-P often display rigidity and postural instability with dystonic features, whereas those with MSA-C may experience more complex coordination deficits compounded by dystonia. In CBD, limb dystonia is commonly asymmetric and may occur alongside ideomotor apraxia, further complicating the motor presentation. These dystonic features in MSA and CBD restrict voluntary movement and intensify fall risk, underscoring the need for targeted rehabilitation combined with pharmacologic therapy.

Pharmacologic treatment of dystonia in PD and APS generally begins with optimization of dopaminergic therapy. Levodopa remains the cornerstone, especially in dopa-responsive dystonia, where dramatic clinical improvement can occur. As a dopamine precursor, levodopa crosses the blood–brain barrier and is converted to dopamine within the basal ganglia, enhancing motor control by modulating both direct and indirect pathways. However, long-term levodopa use can paradoxically induce dystonic symptoms, particularly during “off” periods or at peak-dose dyskinesia, necessitating careful titration and adjunctive strategies [22]. Anticholinergic medications may also be considered, especially in younger patients, to restore dopaminergic–cholinergic balance within the striatum [23]. By inhibiting muscarinic acetylcholine receptors, these drugs reduce overactive cholinergic interneuron activity, alleviating tremor and dystonia, although cognitive side effects limit their use in older populations. Other pharmacologic options include clonazepam and baclofen. Clonazepam, a benzodiazepine that acts as a positive allosteric modulator of gamma-aminobutyric acid (GABA)-A receptors, enhances inhibitory neurotransmission and may reduce dystonic spasms by dampening neuronal excitability within cortical–subcortical motor circuits [24]. It has demonstrated benefit in both focal and generalized dystonia, particularly when dystonia coexists with spasticity or involuntary posturing. Baclofen, a GABA-B receptor agonist, reduces excitatory neurotransmitter release at the spinal level while enhancing inhibitory tone, thereby lowering muscle tone and spasticity [25]. Its use in dystonia, particularly of spinal or segmental origin, is supported in selected cases, though central side effects require careful monitoring. For patients with medically refractory focal dystonia—especially cervical dystonia or pronounced axial involvement as seen in PSP—botulinum toxin injections remain a cornerstone treatment. By blocking acetylcholine release at the neuromuscular junction, botulinum toxin induces temporary chemo-denervation, reducing pain and improving function [26]. Its utility in managing axial rigidity and pharmacoresistant dystonia underscores its central role in focal dystonia therapy in patients with APSs.

MANAGEMENT OF NON-MOTOR SYMPTOMS IN GAIT AND BALANCE REHABILITATION

Non-motor symptoms exert a profound impact on mobility, functional safety, and fall risk in both PD and APSs, and must therefore be considered integral components of gait and balance rehabilitation. Among autonomic dysfunctions, orthostatic hypotension is particularly critical, as it poses a direct risk for sudden drops in blood pressure during positional changes, such as rising from a chair or bed. These episodes may lead to dizziness, syncope, and falls, often resulting in serious injuries including fractures. Rehabilitation programs should address this through a combination of pharmacologic management and physical countermeasures. Practical strategies include slow and graded postural transitions, use of compression garments, and lower body strengthening to improve orthostatic tolerance.

Neurogenic bladder, another common autonomic feature, indirectly increases fall risk by altering daily activity patterns. Nocturia and urinary urgency heighten the likelihood of falls, particularly during nighttime bathroom visits in low-light conditions. Reduced visual feedback in darkness and sleep fragmentation due to frequent nocturnal voiding may further contribute to daytime fatigue and impaired physical stability.

To mitigate these risks and promote independence, rehabilitation should incorporate home safety modifications, caregiver education, and individualized strategies tailored to each patient’s functional status. An integrated approach that addresses both motor and non-motor symptoms is essential to optimize safety and enhance independence.

CONCLUSION

Motor symptoms such as bradykinesia, rigidity, postural instability, and gait disturbance remain major contributors to disability in PD and APSs. Developing rehabilitation strategies that adapt to disease stage is essential for maintaining mobility and independence. In the early phase, emphasis should be placed on self-initiated exercise and compensatory strategies that support long-term function. As the disease progresses, rehabilitation must be adjusted to manage increasing motor challenges with targeted interventions and comprehensive fall-prevention efforts. For APSs, syndrome-specific features, including axial rigidity in PSP, cerebellar ataxia in MSA, and apraxia in CBD, necessitate individualized rehabilitation approaches. Dystonia, though frequently underrecognized, can further compromise mobility and should be actively evaluated and treated through both pharmacologic and physical therapy interventions. Although the primary focus of this review is motor rehabilitation, non-motor symptoms also play a crucial role in influencing gait, balance, and overall functional safety. Incorporating these factors into rehabilitation planning is essential for developing safe, effective, and patient-centered strategies for individuals with PD and related disorders.